Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study.

Giacomo SgallaErminia Lo GrecoMariarosaria CalvelloFrancesco VaroneBruno IoveneStefania CerriPierluigi DonatelliAda VancheriMauro PavoneFabrizio LuppiCarlo VancheriLuca Richeldi

Published in: Respirology (Carlton, Vic.) (2020)

In patients receiving antifibrotics following a working diagnosis of IPF, disease progression rates were similar to patients with a confident diagnosis of IPF according to consensus guidelines, supporting the rationale for treatment initiation in these patients by expert multidisciplinary teams.

Keyphrases

idiopathic pulmonary fibrosis
interstitial lung disease
clinical practice
newly diagnosed
ejection fraction
prognostic factors
patient reported outcomes
combination therapy
patient reported